Breaking the Differentiation Bottleneck of hiPSC-Derived Mast Cells — New UA Cytokine Kit Now Available!
From pluripotent stem cells to functional mast cells, a one-step professional solution
- Recent Advances
- Product Information
Recent Advances
Breaking the hiPSC Mast Cell Differentiation Bottleneck—UA Cytokine Kit Now Available!
A Turnkey Professional Solution from Pluripotent Stem Cells to Functional Mast Cells
In the fields of allergic disease research, immunotherapy development, and drug safety evaluation, mast cells (MCs) serve as critical immune effector cells. However, the establishment of in vitro models has long been constrained by challenges such as difficult primary cell isolation, donor variability, and limited expansion capacity.
UA BIOSCIENCE introduces the UA090059 iPSC-to-Mast Cell Differentiation Cytokine Kit, offering a stable and efficient pathway from hiPSCs to high-purity functional mast cells.
Key Features
✅ Validated Differentiation Protocol
✅ Detailed Protocol with Precise Dosage Guidance (Eliminates Optimization Steps)
✅ Comprehensive Cytokine Cocktail for Full Differentiation
✅ Multiple Sizes Available, Ready-to-ShipApplications
| Research Area | Use Cases |
|---|---|
| Allergy & Immunology | IgE-mediated hypersensitivity mechanisms, degranulation studies |
| Drug Development | Drug sensitization assessment, mast cell stability testing |
| Cancer Immunology | Tumor microenvironment mast cell function analysis |
| Inflammatory Diseases | Disease modeling (asthma, urticaria, mastocytosis) |
| Cell Therapy | Mast cell-based immunomodulatory therapy exploration |
* Applicable research fields and corresponding use cases.
Validation Data

iPSCs exhibit c-Kit⁻/FcεRI⁻ phenotype. After Mast Cell Media I culture, c-Kit and FcεRI remain negative. Following 3-week culture in Mast Cell Media II, 97.0% of cells become c-Kit⁺/FcεRI⁺, confirming mature mast cell (MC) formation.
Product Information













